Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 5/20 | 0.48 |
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | PRF1 | P14222 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19509223 | 0.92 | CYP3A4 (0.50) | CYP3A4MAPTLMNAGAAMAOB | |
| SCHEMBL28619755 | 0.84 | CYP3A4 (0.51) | CYP3A4MAPTLMNAGAAMAOB | |
| SCHEMBL16523540 | 0.84 | CYP3A4 (0.51) | CYP3A4MAPTLMNAGAAMAOB | |
| SCHEMBL27094979 | 0.84 | CYP3A4 (0.47) | CYP3A4MAPTLMNAGAAMAOB | |
| SCHEMBL32666728 | 0.84 | CYP3A4 (0.47) | CYP3A4MAPTLMNAGAAMAOB | |
| SCHEMBL13412837 | 0.84 | CYP3A4 (0.63) | CYP3A4MAPTLMNAGAAMAOB | |
| SCHEMBL30190209 | 0.80 | CYP3A4 (0.47) | CYP3A4MAPTLMNAGAAMAOB | |
| SCHEMBL7000739 | 0.80 | CYP3A4 (0.75) | CYP3A4MAPTLMNAGAAMAOA | |
| SCHEMBL26774121 | 0.80 | MAPT (0.41) | CYP3A4MAPTLMNAGAAMAOB | |
| SCHEMBL26774120 | 0.80 | MAPT (0.41) | CYP3A4MAPTLMNAGAAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3035923-B1 | DITHIOL MUCOLYTIC AGENTS | PARION SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-9963427-B2 | Dithiol mucolytic agents | PARION SCIENCES, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963427-B2 | Dithiol mucolytic agents | PARION SCIENCES, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963427-B2 | Dithiol mucolytic agents | PARION SCIENCES, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20160318861-A1 | NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS | PARION SCIENCES, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318861-A1 | NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS | PARION SCIENCES, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318861-A1 | NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS | PARION SCIENCES, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015026601-A2 | DITHIOL MUCOLYTIC AGENTS | JOHNSON MICHAEL R (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20150056305-A1 | DITHIOL MUCOLYTIC AGENTS | PARION SCIENCES, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150056305-A1 | DITHIOL MUCOLYTIC AGENTS | PARION SCIENCES, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
| EP-1910325-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010085-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056305-A1 | DITHIOL MUCOLYTIC AGENTS | MUC1, DNASE1, MMP8 | CYP3A4 3760/4885MAPT 3593/4885LMNA 3974/4885 |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | CYP3A4 315/4885MAPT 1744/4885LMNA 2931/4885 |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | CYP3A4 20/4885MAPT 1148/4885LMNA 3994/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | CYP3A4 3/4885MAPT 2131/4885LMNA 3538/4885 |
| US-20160318861-A1 | NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS | MUC1, MGMT, ESD | CYP3A4 1700/4885MAPT 3339/4885LMNA 4656/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | CYP3A4 315/4885MAPT 1744/4885LMNA 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.